Work

Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC

Year: 2008

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2008.26.15_suppl.8027

Authors: P. A. Janne, J. H. Schellens, J. A. Engelman, S. G. Eckhardt, R. Millham, L. J. Denis, C. D. Britten, S. G. Wong, D. S. Boss, D. R. Camidge

Institutions: University of California, Los Angeles, Pfizer (United States), The Netherlands Cancer Institute, Massachusetts General Hospital, Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2519620281

Cites:

Cited by: 66

Related to: 10